the face of advances in medicine or new methods of conducting research. As a result, the regulatory framework must continually evolve. Even understanding this, one might reasonably ask: Why are changes being proposed now?
Over the last several decades, the volume and nature of human subjects research have changed considerably. 6 Human subjects research has grown in scale while becoming more diverse. Today, studies are more likely to enroll large numbers of research participants and to span multiple sites. 7 Research participants are more likely to be collaborative partners in research, rather than simply the objects of study. 8 Other developments include:
[a]n expansion in the number and type of clinical trials, as well as observational studies and cohort studies; a diversification of the types of social and behavioral research being used in human subjects research; increased use of sophisticated analytic techniques for use with human biospecimens; and the growing use of electronic health data and other digital records to enable very large data sets to be analyzed and combined in novel ways. 9 These changes have been accompanied by considerable debate about the ethics of human subjects research. Proposed revisions to both the Common Rule and the CIOMS Guidelines emerged from this rich context of substantive change and normative debate.
Although the Common Rule and the CIOMS Guidelines both pertain to the conduct of human subjects research, they are qualitatively different. The Common Rule contains the US federal regulations governing most research with human subjects funded or conducted by the government. 10 In contrast, the CIOMS Guidelines were written for application 'particularly in developing countries' 11 and are not legally binding. They have, however, been codified in or influenced national laws and regulations. Appreciation of these differences is essential to understanding why the proposed changes were drafted the way they were, the practical effects these proposed changes might have on human subjects research, and the relative urgency with which the research community is critiquing them. This Development will proceed as follows. Part I will examine the Notice of Proposed Rulemaking (NPRM) that proposes changes to the Common Rule. Part II will highlight proposed changes to the CIOMS Guidelines. Part III concludes. 208 r Recently proposed changes to legal and ethical guidelines governing human subjects research of these changes are controversial and involve compromise, I suggest that they are, on the whole, positive and should be welcomed as an advance over the status quo.
I. NOTICE OF PROPOSED RULEMAKING
Federal laws governing human subjects research demonstrate 'a societal commitment to the advancement of scientific knowledge provided that the advances occur in accord with ethically sound principles and practices'. 12 The Common Rule, now codified in separate regulations by 18 Federal departments and agencies, 13 is 'a uniform regulatory floor for human subjects research... which generally requires informed consent, independent ethical review, and the minimization of avoidable risks'. 14 Within the US context, there has been documentation of problems with the extant regulations and their application. For instance:
Informed-consent documents grow ever longer and consistently exceed the eighth-grade reading level, with wide variation in participants' comprehension. Researchers have documented unjustified variation in assessments of studies' risks and benefits. And the review system is inefficient, with numerous [institutional review board (IRB)] reviews for multicenter studies delaying initiation of research for months or years, despite little evidence that multiple reviews enhance protections. 15 Many, therefore, feel that changes are needed to enhance protections for research participants, improve efficiency, and reflect the changing nature of research.
In November 2009, representatives from the Department of Health and Human Services (HHS) and other departments convened to reform the Common Rule with the dual aims of enhancing research participant protections and increasing the efficiency of the research oversight process. 16 Those meetings led to the release of an Advanced Notice of Proposed Rulemaking (ANPRM) in July 2011. 17 In September 2015, the long awaited NPRM 18 was published in the Federal Register. 19 The NPRM was initially open for public comment through December 7, 2015; however, the comment period was subsequently extended until January 6, 2016, after widespread demands for additional time to consider and comment on the complex proposals. 20 With the comment period now closed, it is up to regulators to determine whether to proceed with the final 12 rule. 21 The timeline is unclear, and there is no legal requirement for a final rule at all, but many have advocated moving forward as quickly as possible.
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Coming in at 131 Federal Register pages, the NPRM proposes several significant changes to the Common Rule aimed at: improving the informed consent process; strengthening consent requirements for use of stored biospecimens in research; limiting use of waivers and alteration of consent for research involving biospecimens; excluding certain kinds of activities from coverage under the Common Rule; adding additional categories of exempt research; mandating that US institutions engaged in cooperative research rely on a single IRB; eliminating continuing review for studies that undergo expedited review and for studies that have completed study interventions; and extending the scope of the policy to cover all clinical trials conducted at US institutions that receive federal funding for human subjects research. 23 The NPRM was highly anticipated and, therefore, subject to great scrutiny upon publication. There has been a flood of commentary from researchers, individuals involved in research oversight, and research ethicists. Here, I will focus on three prominent changes: consent for research use of biospecimens; review of cooperative research by a single IRB; and informed consent documents.
I.1. Use of Stored Biospecimens
Biospecimens are materials taken from the human body-for instance, blood, tissue, saliva, and urine-that can be used for either clinical or research purposes. 24 'Billions' of biospecimens are now in storage. 25 Because biospecimens contain a tremendous amount of biological information, they can be used by researchers to identify 'the role that genes play in disease formation... develop new diagnostic tests and targeted treatments for specific diseases and to investigate how genes interact with environmental factors'. 26 They may also lay the necessary foundation for 'personalized medicine', treatments customized to an individual's genetic profile. 27 At present, the Common Rule applies to the secondary research use of biospecimens (meaning use of specimens originally collected for another purpose, either clinical care http://www.hhs.gov/ohrp/sachrp/commsec/november3,2015lettertothehhssecretary.html ( accessed Jan 4, 2016). 21 Another possibility is that HHS could issue a second NPRM rather than a final rule, an approach advocated by several commenters. In almost all circumstances, the NPRM would require informed consent for use of stored biospecimens in secondary research. That consent would generally be obtained by means of 'broad'consent, a template for which would be provided by the regulators if the rule is finalized. 31 Broad consent has been defined as 'consent for an unspecified range of future research subject to a few content and/or process restrictions. Broad consent is less specific than consent for each use, but more narrow than open-ended permission without any limitations (ie. 'blanket'consent)'. 32 The intent of broad consent is to show respect for individuals by allowing them to decide whether they want their biospecimens and data used for research while obviating the need for consent to each subsequent research project.
These proposals are, in part, a response to criticisms that the Common Rule cannot account for recent advances in science that pose novel risks for privacy and confidentiality. 33 The preamble to the NPRM explains that with already existing tools and technologies, 'biospecimens can be used to generate information unique to individuals and therefore cannot be truly deidentified'. 34 The NPRM also points to the autonomy interests of biospecimen sources.
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It is widely accepted that requiring consent for the use of biospecimens in secondary research will create challenges for the research community. These include additional administrative burdens to implement a broad consent process and to track the consent status of individual biospecimens. 36 In response to comments received regarding the ANPRM, the NPRM proposes that the new definition of 'human subject' would apply prospectively, and compliance with the provision would be delayed until three years after publication of a final rule.
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I.2. Review of Cooperative Research by a Single IRB
An IRB is an administrative body with the authority to approve, require modifications in, or disapprove human subjects research activities conducted under the auspices of 28 'Human subject' is currently defined as 'a living individual about whom an investigator ... conducting research obtains (1) data through intervention or interaction with the individual or (2) the institution with which it is affiliated. 38 Currently, many studies are carried out at multiple sites. 39 This can help with recruitment of a larger number of research participants and more diverse study populations. At present, IRB approval is typically required at each study site. A criticism of the current redundant review process is that it can create inefficiencies and add delays without increasing the protections enjoyed by research participants. 40 The NPRM would therefore require participating US institutions engaged in cooperative research to rely on a single IRB. 41 This proposal is consistent with a draft policy issued by the National Institutes of Health (NIH) to promote the use of single IRBs in multi-site clinical research studies. 42 The draft NIH policy would expect all NIHfunded multi-site studies carried out in the United States to use a single IRB. 43 The response to NIH's proposed policy is characterized in the NPRM as 'robust and largely supportive'. 44 One concern of those opposed to mandatory use of a single IRB is the potential for loss of accountability and 'increased liability for the institutions where research is conducted but where the reviewing IRB is not located'. 45 To protect against this concern, the NPRM proposes to 'give Common Rule departments and agencies the authority to enforce compliance directly against unaffiliated IRBs that are not operated by an assured institution'. 46 Others are concerned that the proposal may not actually enhance efficiency if there is a need for robust agreements to establish the authority of the central and participating IRBs, to define respective responsibilities and to structure the means for interinstitution information-sharing. 47 Moreover, it may be difficult for investigators to learn the system of multiple IRBs, rather than just their own institution's system, and special issues presented by local populations may be overlooked.
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I.3. Informed Consent Documents
As mentioned above, there are long-standing complaints about informed consent documents, 'namely, that they are too long, too complicated, and filled with legal text designed more to protect institutions than [research] participants'. 49 Under the proposed regulations, the content of these forms would be shortened and limited to specific elements outlined in the rule-described by some as 'essential information that a reasonable person would want to know' 50 -with non-essential information moved into a separate appendix. 51 The reforms would require researchers to inform research participants that biospecimens might be used for commercial profit (a move motivated by high-profile cases such as that of Henrietta Lacks 52 ), tell them whether they will be informed of clinically relevant findings, and ask them whether they are willing to be re-contacted for additional research. 53 Notably, '[t]he reforms don't include a requirement, advocated by some commentators, for routine formal assessment of participants' mental competency to consent and comprehension of disclosed information'.
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II. CIOMS ETHICAL GUIDELINES
CIOMS is an international non-governmental organization founded under the auspices of the World Health Organization (WHO) and the United Nations Educational, Scientific, and Cultural Organization (UNESCO) in 1949. 55 The CIOMS guidelines are for application of the principles of the Declaration of Helsinki, 'a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data', 56 'particularly in developing countries, given their socioeconomic circumstances, laws and regulations, and executive and administrative arrangements'. 57 Therefore, in addition to broader developments in biomedical research and the field of research ethics, the Executive Committee of CIOMS cites the 2013 revision of the Declaration of Helsinki as a factor in its decision to revise. 58 The proposed revisions to the CIOMS Guidelines were released in September 2015. CIOMS invited public comments through March 1, 2016. The Working Group will review the comments and then submit a final document to the Executive Committee of CIOMS for approval.
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II.3. Reimbursement and Compensation for Research Participants
The practice of offering payment to individuals in exchange for their participation in human subjects research is generally recognized as important to recruitment. 74 Yet, the question of whether payment is a 'necessary evil' or legitimate compensation for services rendered remains a source of debate. Unfortunately, the various laws, regulations, and ethical guidelines that govern the conduct of human subjects research offer relatively little in the way of specific guidance about the factors and/or features that render offers of payment ethically acceptable. 75 Proposed Guideline 13, Reimbursement and Compensation for Research Participants, takes a strong stance on offers of payment to research participants. While the 2002 CIOMS Guidelines state that research participants 'may be reimbursed', 76 proposed Guideline 13 asserts that participants 'must be reasonably reimbursed for direct and indirect expenses incurred during the research, such as travel costs and lost earnings, and compensated reasonably for inconvenience and time spent'. 77 As the accompanying commentary notes, '[p]articipants should not have to pay for making a contribution to the social good of research'. 78 While acknowledging ethical concerns related to undue inducement, 79 the commentary points out that '[e]specially when the research poses low risks, providing compensation for participating usually does not raise concerns about undue inducement'. 80 This proposal may be particularly useful in practice. Among those engaged in human subjects protections, there is wide agreement about the contextual nature of undue influence and the difficultly of establishing a bright line between mere and undue inducements. 81 As a result of this difficulty, many IRBs are likely to adopt unnecessarily conservative approaches to offers of payment, which may result in under-payment and even exploitation of research participants. 82 Therefore, proposed Guideline 11's recognition of the need to reimburse and its effort to minimize worries about undue inducement for low-risk research is a welcome change.
III. CONCLUSION
Changes have recently been proposed to two influential documents in human subjects research: the Common Rule and the CIOMS Guidelines. The proposed changes are a response, in part, to developments in the conduct of human subjects research and a perceived need for greater protections for research participants. It is not surprising, therefore, that some similar issues-particularly biospecimens-have garnered attention in both the NPRM and the proposed CIOMS Guidelines.
This Development was finalized after the comment periods were over but before either the final rule or guidelines were made publically available. Open questions include how long it will take for these documents to be finalized and how, if at all, the final products will differ from the proposed versions. For reasons identified above, many stakeholders in human subjects research-including myself-will likely see the final results both as an improvement over the existing documents but also as a compromise. Nevertheless, if past experience is any guide, the research community will be working with the final products for some time.
